Andres G. Digenio

Biography

Dr. Digenio joined Akcea as VP of Clinical Development in June 2015. Prior to joining Akcea, he was Executive Director at Ionis Pharmaceuticals, working as the clinical development lead for the lipid franchise (apoC-III, Apo(a) and ANGPTL3 antisense oligonucleotides). Before that Dr. Digenio was Senior Medical Director at Sanofi where he was appointed to lead the U.S. launch of rimonabant (CB1 blocker program for the treatment of obesity, diabetes and CV Disease). He subsequently supported the development of AVE5530 (cholesterol absorption inhibitor), led the cardiovascular platform for Lantus and Apidra and was the clinical lead for lixisenatide (GLP-1 agonist), responsible for overseeing its launch in the US. Prior to joining Sanofi, Dr. Digenio was Senior Medical Director at Pfizer, where he supported the lead CETP inhibitor development program (torcetrapib), was responsible for the atherosclerosis biomarker program, and later supported the phase 3 clinical development program for otanabant (CB1 blocker). Prior to joining Pfizer, Dr. Digenio was in academia holding the position of Assistant Professor of Medicine in the Department of Cardiology at Vanderbilt University. Before coming to the U.S., Dr. Digenio was the medical director of a large primary and secondary prevention program in Johannesburg, South Africa.

Research Interest

His research interest in Business and Management